CRISPR Therapeutics AG (BSP:C2RS34) Cyclically Adjusted Book per Share: R$11.67 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:C2RS34 CRISPR Therapeutics AG BSP:C2RS34
16 GF Score
Price R$33.57
GF Value R$2.66
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Cyclically Adjusted Book per Share?

CRISPR Therapeutics AG BSP:C2RS34 16 Cyclically Adjusted Book per Share is R$11.67 as of Jun. 2026. GuruFocus rates BSP:C2RS34 with a GF Score™ of 16/100 and a GF Value™ of R$2.66 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

CRISPR Therapeutics AG's adjusted book value per share for the three months ended in Jun. 2026 was R$92.586. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$11.67 for the trailing ten years ended in Jun. 2026.

During the past 12 months, CRISPR Therapeutics AG's average Cyclically Adjusted Book Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-08-09), CRISPR Therapeutics AG's current stock price is R$33.57. CRISPR Therapeutics AG's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was R$11.67. CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio of today is 2.88.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of CRISPR Therapeutics AG was 4.31. The lowest was 2.00. And the median was 3.13.


CRISPR Therapeutics AG  (BSP:C2RS34) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=33.57/11.67
=2.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of CRISPR Therapeutics AG was 4.31. The lowest was 2.00. And the median was 3.13.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


CRISPR Therapeutics AG Cyclically Adjusted Book per Share Related Terms


CRISPR Therapeutics AG Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for CRISPR Therapeutics AG's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG Cyclically Adjusted Book per Share Chart

CRISPR Therapeutics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CRISPR Therapeutics AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 11.67

BSP:C2RS34 vs MANE, EWTX, CAI: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CRISPR Therapeutics AG Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio falls into.


BSP:C2RS34
16GF Score
CRISPR Therapeutics AG BSP:C2RS34
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CRISPR Therapeutics AG Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CRISPR Therapeutics AG's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=92.586/108.5600*108.5600
=92.586

Current CPI (Jun. 2026) = 108.5600.

CRISPR Therapeutics AG Quarterly Data

Book Value per Share CPI Adj_Book
201609 -5.114 99.604 -5.574
201612 19.662 99.380 21.478
201703 16.903 100.040 18.343
201706 16.280 100.285 17.623
201709 13.709 100.254 14.845
201712 15.247 100.213 16.517
201803 20.394 100.836 21.956
201806 21.242 101.435 22.734
201809 33.259 101.246 35.662
201812 29.372 100.906 31.600
201903 27.714 101.571 29.621
201906 26.499 102.044 28.191
201909 44.180 101.396 47.302
201912 63.436 101.063 68.142
202003 71.106 101.048 76.392
202006 73.774 100.743 79.498
202009 102.740 100.585 110.886
202012 115.836 100.241 125.450
202103 134.346 100.800 144.689
202106 172.102 101.352 184.341
202109 173.492 101.533 185.500
202112 176.240 101.776 187.988
202203 144.362 103.205 151.853
202206 135.668 104.783 140.559
202209 130.939 104.835 135.592
202212 125.301 104.666 129.962
202303 122.507 106.245 125.177
202306 111.052 106.576 113.120
202309 107.433 106.570 109.440
202312 115.254 106.461 117.526
202403 122.322 107.355 123.695
202406 125.457 107.991 126.118
202409 125.872 107.468 127.151
202412 137.478 107.128 139.316
202503 121.959 107.722 122.907
202506 107.377 108.075 107.859
202509 109.461 107.710 110.325
202512 109.338 107.200 110.725
202603 98.452 108.060 98.908
202606 92.586 108.560 92.586

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of R$11.67 mean?
CRISPR Therapeutics AG (BSP:C2RS34) has a Cyclically Adjusted Book per Share of R$11.67 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's Cyclically Adjusted Book per Share too high?
CRISPR Therapeutics AG's current Cyclically Adjusted Book per Share is R$11.67. Overall, CRISPR Therapeutics AG has a GF Score™ of 16/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Cyclically Adjusted Book per Share compare to MANE and EWTX?
CRISPR Therapeutics AG's Cyclically Adjusted Book per Share of R$11.67 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current Cyclically Adjusted Book per Share is R$11.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (BSP:C2RS34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$2.66, compared to a current price of R$33.57 — trading 1162% above its estimated fair value. The current Cyclically Adjusted Book per Share is R$11.67. CRISPR Therapeutics AG's overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For CRISPR Therapeutics AG (BSP:C2RS34), the current Cyclically Adjusted Book per Share is R$11.67 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CRISPR Therapeutics AG (BSP:C2RS34) Overvalued in 2026?

Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued. The current stock price of R$33.57 is trading 1162% above its estimated GF Value™ of R$2.66. GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.

Key valuation signals for BSP:C2RS34:

  • Cyclically Adjusted Book per Share: R$11.67
  • GF Value™: R$2.66 vs. price of R$33.57 (1162% above fair value)
  • GF Score™: 16/100 with 3 warning signs

No single metric tells the full story. See the BSP:C2RS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
16GF Score

Get the complete analysis for BSP:C2RS34

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$33.57
Price
R$2.66
GF Value